Delayed onset of action of antidepressant drugs. Survey of recent results

European Psychiatry

Volumn 12, Issue 4, 1997, Pages 166-176

  Stassen, H H ^a   Angst, J ^a   Delini Stula, A ^a,b  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b Roche Intl Clin Research Center   (France)

Author keywords

Antidepressants; Onset of action; Placebo; Response to treatment

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; IMIPRAMINE; MOCLOBEMIDE; OXAPROTILINE; PLACEBO;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030962197     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(97)89100-6     Document Type: Conference Paper

References (27)

1. Angst J. Time-lag of antidepressant effect. In: Symposia Medica Hoechst 13, Symposium Rome 1977: Depressive Disorders. Stuttgart: Schattauer, 1978;468
2. Angst J, Delini-Stula A, Stassen HH. Is a cutoff score a suitable measure for treatment outcome? A methodological metaanalysis. Hum Psychopharmacol 1993;8:311-7
3. Angst J, Stassen HH. Methodische Aspekte von Studien zur antidepressiven Wirksamkeit. In: Steinberg R, Philipp M, Möller HJ, eds. Spezielle Aspekte der antidepressiven Therapie. Munich: MMV Medizin Verlag, 1994;147-66
4. Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 1990;51: 14-20
5. DaPrada M, Kettler R, Keller HH, Haefely WE. Neurochemical effects in vitro and in vivo of the antidepressant RO 11-1163, a specific and short-acting MAO-A inhibitor. Mod Prob Pharmacopsychiatry 1983;19:231-45
6. Donlon PT, Biertuemphel H, Willenbring M. Amoxapine and amitriptyline in the outpatient treatment of endogenous depression. J Clin Psychiatry 1981;42:11-5
7. Delini-Stula A, Hauser K, Baumann P et al. Stereospecificity of behavior and biochemical responses to oxaprotiline - a new antidepressant. Adv Biochem Psychopharmacol 1982;31: 265-75
8. Gachoud JP, Mikkelsen H, Ammar S, Widlöcher D, Jouvent R. Theoretical consideration and perspectives on the onset of action of moclobemide. Psychopharmacology 1992;106: 96-7
9. Greenhouse JB, Kupfer DJ, Frank E, Jarrett DB, Rejman KA. Analysis of time to stabilization in the treatment of depression: biological and clinical correlates. J Affective Disord 1987;13:259-66
10. Greenhouse JB, Stangl D, Bromberg J. An introduction to survival analysis: statistical methods for analysis of clinical trial data. J Consult Clin Psychol 1989;57:536-44
11. Grey P. Fluoxetine and onset of its therapeutic effect. Am J Psychiatry 1993; 150:984
12. Hekimian LJ, Firedhoff AJ, Deever E. A comparison of the onset of action and therapeutic efficacy of amoxapine and amitriptyline. J Clin Psychiatry 1978;39:633-7
13. Katz MM, Koslow SH, Maas JW et al. The timing, specificity and clinical prediction of tricycling drug effects in depression. Psychol Med 1987;17:297-309
14. Khan A, Cohen S, Dager S, Avery DH, Dunner DL. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. J Affective Disord 1989;17: 33-8
15. Kuny S, Stassen HH. Speaking behavior and voice sound characteristics in depressive patients during recovery. J Psychiat Res 1993;27:289-307
16. Mason BJ, Kocsis JH, Frances AJ, Mann JJ. Amoxapine versus amitriptyline for continuation therapy of depression. J Clin Psychopharmacol 1990;10:338-43
17. Meya U, Fichte K. Antidepressiver Wirkungseintritt von Rolipram, einem Antidepressivum mit einem neuen Wirkmechanismus, im Vergleich zu Imipramin. Nervenarzt 1991;62:288-91
18. Quitkin FM, Rabkin JG, Markowitz JM et al. Use of pattern analysis to identify true drug response. Arch Gen Psychiatry 1987;44:259-64
19. Quitkin FM, McGrath PJ, Rabkin JG et al. Different types of placebo response in patients receiving antidepressants. Am J Psychiatry 1991a;148:197-203
20. Quitkin FM, Rabkin JG, Stewart JW et al. Heterogeneity of clinical response during placebo treatment. Am J Psychiatry 1991b;148:193-6
21. Quitkin FM, Stewart JW, McGrath PJ et al. Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993;150:566-70
22. Roffmann M, Gould EF, Brewer SJ et al. A double blind comparative study of oxaprotiline with amitriptyline and placebo in moderate depression. Curr Ther Res 1982;32: 247-56
23. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993;3:127-35
24. Stassen HH, Angst J, Delini-Stula A. Severity at baseline and onset of improvement in depression. Meta-analysis of imipramine and moclobemide versus placebo. Eur Psychiatry 1994:9:129-36
25. Wachtel H. Dysbalance of neuronal second messager function in the aetiology of affective disorders: a pathophysiological concept hypothesising defects beyond first messenger receptors. J Neurol Transm 1989;75:21-9
26. Waldmeier PC, Baumann PA, Hauser K, Maître L, Storni A. Oxaprotiline, a nonadrenaline uptake inhibitor with an active and inactive enantiomer. Biochem Pharmacol 1982;31:2169-76
27. Willner P. Sensitization to the actions of antidepressant drugs. In: Emmett-Oglesby MW, Goudie AJ, eds. Psychoactive Drugs tolerance and sensitization. Clifton: Humana Press, 1989;407-59